ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1592

Serious Infections in SLE- Incidence, Associated Factors, Impact and Trends over Two Decades

Rudrarpan Chatterjee, Sarit Sekhar Pattanaik, Durga P Misra, Vikas Agarwal, Able Lawrence and Amita Aggarwal, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

Meeting: ACR Convergence 2022

Keywords: Infection, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Abstracts: SLE – Diagnosis, Manifestations, and Outcomes II: Complications

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: Infections are a major cause of morbidity and mortality in systemic lupus erythematosus (SLE). We assessed the incidence and risk factors for major infections in adult SLE.

Methods: We carried out a retrospective review of 1354 patients of SLE (ACR 1997 criteria) with age ≥18 years visiting the rheumatology clinic at a single centre between 2000 to 2020. Clinical details were retrieved from clinical case records and supplemented with data from the hospital electronic health records. Serious infection was defined as the need for hospitalization, or infection resulting in disability or death. Cox regression was used to determine factors associated with a serious infection and the effect of each serious infection on overall survival.

Results: Among the 1354 patients (1258 females) with a mean age of 30.32 ±9.42 years and a cumulative follow up of 7127.89 person-years. A total of 439 major infections occurred in 339 (25.03% of the cohort) individuals at a rate of 61.6 serious infections per 1000 person-years of follow-up. Recurrent infections occurred in 101 (7.45%) patients. The average number of infections increased from 9.9 to 23.7 per year from 2000-09 to 2010-19.

Among the microbiologically confirmed cases (79.9% of cases) Tuberculosis (81) was the most common organism followed by S. aureus (65), E. coli (51), K. pneumoniae (29), P. aeruginosa (29), S. pneumoniae (20), Acinetobacter spp. (9), E. fecalis (9), Nocardia (4), Salmonella (3), Proteus (1) and Listeria (1). Forty (9.1%) opportunistic infections occurred: Cytomegalovirus (11), disseminated Herpes zoster (10), invasive candidiasis (5), cryptococcal meningitis (5), histoplasmosis (2), and 1 each of Aspergillus flavus pneumonia, CNS toxoplasmosis and Giardia lamblia. On multivariate analysis SLEDAI-2K(HR 1.02, 1.01-1.05), gastrointestinal involvement (HR 2.75, 1.65-4.69), current steroid dose (HR 1.65,1.55-1.76), average cumulative steroid dose per year (HR 1.007, 1.005-1.009) were associated with serious infection and higher albumin (HR 0.65, 0.56-0.76) was protective.

Serious infection led to more damage accrual (1 vs 0). Serious infection-free survival at 1 year and 5 years was 82.9% (80.8-85) and 73.8% (71.1-76.6). There were 119 deaths with infection attributable mortality in 65 (54.6%). Hazard ratio for mortality was 18.2, 32.7, and 81.6 for the first, second, and third serious infection.

Conclusion: Serious infections remain a major cause of mortality and damage accrual in SLE and are associated with higher disease activity, gastrointestinal involvement, hypoalbuminemia, current and cumulative steroid dose. TB prophylaxis in patients with SLE should be considered in endemic areas, especially when using high-dose steroid therapy.

Supporting image 1

The bar diagram depicts the number of instances of tuberculosis per year compared to other serious infections from the year 200 to 2022. The dashed line represents the 10 year moving average of all serious infections in the cohort and shows a consistently increasing trend.

Supporting image 2


Disclosures: R. Chatterjee, None; S. Pattanaik, None; D. Misra, None; V. Agarwal, None; A. Lawrence, None; A. Aggarwal, None.

To cite this abstract in AMA style:

Chatterjee R, Pattanaik S, Misra D, Agarwal V, Lawrence A, Aggarwal A. Serious Infections in SLE- Incidence, Associated Factors, Impact and Trends over Two Decades [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/serious-infections-in-sle-incidence-associated-factors-impact-and-trends-over-two-decades/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serious-infections-in-sle-incidence-associated-factors-impact-and-trends-over-two-decades/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology